

32. (NEW) A vaccine for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising:

*Sub B6*  
EHV-1 KyA virus inactivated by treatment with a chemical inactivating agent which includes ethylenimine, a derivative of ethylenimine or a mixture thereof; and a bioadhesive adjuvant which includes a cross-linked acrylic acid polymer.

33. (NEW) The vaccine of claim 32 further comprising inactivated EHV-4.

34. (NEW) The vaccine of claim 32 further comprising inactivated equine influenza virus.

35. (NEW) The vaccine of claim 34 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A1.

36. (NEW) The vaccine of claim 35 wherein the inactivated EIV virus subtype A1 includes inactivated EIV A1 virus strain A/EQ1/Newmarket/77.

*A1*  
37. (NEW) The vaccine of claim 34 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A2.

38. (NEW) The vaccine of claim 37, wherein the inactivated EIV virus subtype A2 includes inactivated EIV A2 virus strain Newmarket/2/93, inactivated EIV A2 virus strain Kentucky/95 or a mixture thereof.

39. (NEW) The vaccine of claim 34 comprising inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.

40. (NEW) The vaccine of claim 39 comprising inactivated EIV A1 virus strain A/EQ1/Newmarket/77, inactivated EIV A2 virus strain Newmarket/2/93, and inactivated EIV A2 virus strain Kentucky/95.